Nursing · Independent exam preparation
CARN Preparation Guide: Assessment, Acute Safety, and Recovery Care Study Guide
Practise withdrawal triage, medication safety, collaborative care planning, and recovery follow-up through 60 focused CARN concepts and original learning questions.
By CertMedbry · Updated 27 October 2026
Learn to distinguish intoxication from withdrawal, recognize urgent complications, explain medication risks, and coordinate individualized recovery care. This selective guide develops 60 clinical decisions across the five practice domains of the Certified Addictions Registered Nurse examination. The official CARN outline remains the full examination scope, including its separate patient-problem categories. Use the concepts, questions, and flashcards to strengthen reasoning within the registered nurse role.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which credential and examination does this guide cover?
It covers Certified Addictions Registered Nurse (CARN), awarded by the Addictions Nursing Certification Board (ANCB). C-NET provides testing and evaluation services, with PSI identified in the handbook as the testing partner. CARN-AP is a separate advanced-practice examination; its content specifications should not replace the RN blueprint.
CARN Exam — Certified Addictions Registered Nurse · CARN Examination Handbook — Revised January 2026 · ANCB — Statistics & Studies
How many questions are presented, and how many count toward the score?
The January 2026 handbook states that the examination contains 150 questions, including about 25 experimental or pilot questions that are unscored. This implies approximately 125 scored questions; the handbook's pilot count is approximate, so an exact scored count should not be assumed.
What are the duration, delivery method, and item styles?
The handbook allows three hours and describes standard computer-based testing at testing facilities, using multiple-choice questions with one best answer. Some items may share a scenario in a situational set. It does not describe computer-adaptive testing. The official page advertises year-round CBT. The 20 questions here are independent single-best-answer drills.
CARN Examination Handbook — Revised January 2026 · CARN Exam — Certified Addictions Registered Nurse
Which blueprint dates apply?
ANCB identifies the CARN blueprint as updated in 2025 and implemented in 2026. The standalone specifications state implementation in 2026, and the CARN Examination Handbook was revised January 2026. These documents do not establish an exact implementation month or day.
ANCB — Statistics & Studies · CARN Test Specifications (Blueprint) — Implemented 2026 · CARN Examination Handbook — Revised January 2026
How are the five practice domains weighted?
The official weights are biopsychosocial SUD assessment 15%; acute-care assessment 20%; individualized care planning and implementation 15%; education and behavioral change 15%; and care management, treatment, and evaluation throughout recovery, including special populations, 35%. This guide allocates its 60 concepts as 9/12/9/9/21 and its questions and flashcards as 3/4/3/3/7 across those domains.
How do the patient-problem weights relate to the practice domains?
The second blueprint dimension assigns opioid 27%, alcohol 25%, medication misuse 10%, co-occurring psychiatric or comorbid medical disorders 12%, stimulants 15%, cannabinoids or other hallucinogens 6%, and tobacco 5%. These total 100% separately from the practice domains. A question can address both a practice task and a patient problem; the two dimensions should not be added together. The official outline includes topics beyond this selective guide.
What passing standard is documented?
The January 2026 handbook states that passing requires correctly answering 75% of CARN test items and describes Angoff standard setting. Because the same handbook includes approximately 25 unscored pilot items, do not convert that statement into an assumed raw number out of all 150 presented questions. Performance on these learning drills does not predict certification results.
What eligibility and jurisdiction points need attention?
CARN requires current RN licensure or specified equivalency verification, qualifying addictions experience, and continuing education. The handbook specifies at least 2,000 relevant experience hours within three years and 30 continuing education hours within three years, with at least 51% specific to addictions nursing. The official webpage describes supervised direct-client-contact experience more narrowly than the handbook's broader role examples; candidates should resolve that difference with C-NET before applying. Licensure and monitoring-program rules remain subject to the applicable jurisdiction.
CARN Exam — Certified Addictions Registered Nurse · CARN Examination Handbook — Revised January 2026
This guide follows ANCB's CARN blueprint implemented in 2026 and the January 2026 CARN handbook. CARN is the registered nurse specialty credential; CARN-AP has a separate advanced-practice examination and blueprint. These independently authored learning materials are not official examination questions or an endorsed preparation product.
Outline used: CARN Test Specifications (Blueprint), implemented 2026; CARN Examination Handbook revised January 2026. ANCB identifies the blueprint as updated in 2025 and implemented in 2026. Verified for the user-facing date 2026-10-10. The workbook label matches the official CARN credential.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Perform a biopsychosocial SUD assessment15%
1.What does a positive alcohol screen establish, and how is AUD diagnosed?
A positive screen identifies a need for assessment. AUD requires at least two qualifying symptoms within the same 12 months: drinking more or longer than intended; unsuccessful efforts to cut down; substantial time obtaining, using, or recovering; craving; impaired role performance; continued use despite interpersonal problems; reduced important activities; hazardous use; continued use despite physical or psychological harm; tolerance; or withdrawal. Severity is mild with 2–3 symptoms, moderate with 4–5, and severe with six or more. Consumption quantity informs risk but does not independently establish the diagnosis.
Apply it
Two patients report the same drinking quantity. One has no qualifying symptoms after assessment; the other repeatedly drinks longer than intended and has unsuccessfully tried to cut down within the past 12 months. The second pattern supports mild AUD; quantity alone cannot establish AUD in the first patient.
Common pitfall: Counting each example of one symptom as a separate criterion inflates severity. Assess distinct qualifying symptoms within the specified interval.
Screen and Assess: Use Quick, Effective Methods · alcohol-symptom-checklist.pdf
2.Which alcohol-history details change withdrawal risk?
Withdrawal risk depends on more than the reported time of the last drink. Establish usual consumption, recent reduction, previous withdrawal seizures or delirium, repeated withdrawal episodes, concurrent illness, and other sedative exposure. Prior complicated withdrawal is a particularly important warning cue. Current symptoms and vital signs must be interpreted alongside this history because an initially comfortable patient can still develop dangerous withdrawal after a substantial reduction in sustained heavy drinking.
Apply it
A patient who drank heavily for years feels well after reducing intake overnight. A previous withdrawal seizure changes the assessment: communicate elevated risk and obtain a monitored withdrawal plan before relying on the current mild presentation.
Common pitfall: A calm appearance or low symptom score at one moment does not erase a history that predicts later complicated alcohol withdrawal.
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
3.How does an opioid history guide medication initiation?
Establish the opioids used, formulation, route, pattern, recent exposure, previous initiation experiences, and concurrent sedatives. Connect this history with objective withdrawal and current sedation. Buprenorphine has strong mu-opioid receptor affinity but only partial agonist activity: replacing a full agonist can abruptly reduce receptor activation and precipitate withdrawal in a physically dependent patient. Conventional induction therefore requires clinical withdrawal assessment; other initiation protocols have different requirements. Sedative co-exposure also changes respiratory monitoring needs.
Apply it
A patient reports recent methadone use, a previous abrupt worsening after starting buprenorphine, and current benzodiazepine use. Communicate all three findings because they affect initiation planning and respiratory safety, even if the patient primarily requests help with craving.
Common pitfall: Recording only the last-use time misses formulation, dependence, previous initiation response, and co-exposures that alter the treatment decision.
SUBOXONE sublingual film — Prescribing Information, updated December 22, 2025
4.Why is physical dependence different from a sedative use disorder?
Physical dependence is physiological adaptation that can produce withdrawal when a benzodiazepine is reduced or stopped. It can occur during prescribed treatment and does not alone demonstrate a substance use disorder. Assessment for a disorder also considers impaired control, harmful consequences, and the broader behavioral pattern. This distinction supports accurate documentation and safer care: prescribed-use dependence still requires attention to withdrawal risk even when compulsive or harmful use has not been established.
Apply it
A patient takes a prescribed benzodiazepine consistently and develops symptoms after missing doses. Assess withdrawal risk and the medication history while asking separately about loss of control and consequences instead of assuming a use disorder.
Common pitfall: Equating dependence with addiction stigmatizes prescribed treatment; dismissing dependence because medication was prescribed can expose the patient to hazardous abrupt discontinuation.
FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class · Joint Clinical Practice Guideline on Benzodiazepine Tapering
5.How can symptom timing clarify co-occurring mental health needs?
Substance use, intoxication, withdrawal, and independent mental disorders can produce overlapping anxiety, sleep, mood, and behavioral symptoms. Ask when symptoms began, whether they occurred before substance use, and whether they persist during periods without use. These clues inform assessment without requiring premature certainty about causation. Current severity and safety still guide action. A possible substance-related explanation must not delay evaluation of suicidality, psychosis, or major impairment that needs treatment.
Apply it
A patient reports panic during stimulant use and similar episodes years before using stimulants. Record both timelines, assess present safety, and coordinate mental health evaluation while continuing substance-use assessment rather than assigning a single cause immediately.
Common pitfall: Attributing every psychiatric symptom to substances can miss a co-occurring disorder; diagnosing solely from one intoxicated presentation can also distort the clinical picture.
Finding Help for Co-Occurring Substance Use and Mental Disorders
6.What can a reactive hepatitis C antibody result mean?
A reactive HCV antibody result can represent current infection, resolved infection, or biological false positivity. HCV RNA testing determines whether virus is currently detectable and establishes current infection when detected. Completing the antibody-to-RNA sequence is therefore essential. Recent exposure changes interpretation: antibodies may not yet be detectable, so a nonreactive antibody result does not exclude infection after a recent exposure. HCV RNA testing is indicated when recent exposure is suspected.
Apply it
A patient with injection exposure has reactive HCV antibody and assumes active infection is confirmed. Explain the three possible interpretations and arrange HCV RNA testing. For another patient exposed recently despite nonreactive antibody, assess the need for RNA testing.
Common pitfall: Treating reactive antibody as proof of either previous exposure or active infection overlooks biological false positivity; treating a recent negative antibody as definitive can miss early infection.
7.Which stimulant-use details distinguish intoxication from a post-use decline?
Stimulant assessment connects recent exposure with sleep, activity, cardiovascular symptoms, mood, cognition, and other substance use. Agitation and autonomic activation suggest a different immediate problem from exhaustion and depressed mood after use decreases. Neither pattern excludes medical or psychiatric complications. Ask specifically about chest discomfort and suicidal thoughts rather than assuming that a familiar use pattern explains everything. Reassessment is necessary because symptoms and risks can change as stimulant effects diminish.
Apply it
A patient reports several days of stimulant use followed by prolonged sleep and low mood. Establish the exposure timeline, assess suicidal thoughts and medical symptoms, and plan reassessment instead of labeling the presentation simply as fatigue.
Common pitfall: The apparent transition from stimulation to exhaustion does not establish safety; cardiovascular complaints and suicidality require their own assessment despite a plausible substance timeline.
8.How is a biopsychosocial history turned into a useful formulation?
A formulation connects biological risks, psychological symptoms, social conditions, and protective resources with the patient's goals. Assess trauma sensitively by asking permission, explaining the purpose, and avoiding unnecessary demands for details. Ask about housing, relationships, safety, employment, transportation, treatment access, cultural supports, and previous recovery strengths. Protective factors must be concrete and usable, such as a trusted support person or reliable clinic access. Explain how each finding affects safety, engagement, or treatment feasibility.
Apply it
A medically stable patient using methamphetamine has insomnia, trauma-related distress, unstable housing, and a supportive sister. The patient wants to keep working. Formulate sleep and distress as treatment needs, housing and transport as engagement barriers, and the sister and employment goal as potential recovery resources. Ask permission before involving the sister and coordinate accessible care.
Common pitfall: A list of deficits is not a formulation. Verify whether apparently protective relationships are safe and available, and connect findings to specific care priorities.
stud_guideline_document_final.pdf · Finding Help for Co-Occurring Substance Use and Mental Disorders
9.Which nicotine-use history helps explain an unsuccessful quit attempt?
Assess all nicotine products, including cigarettes and vaping products, the timing and situations of use, previous quit attempts, and experience with cessation medicines. Ask what happened before return to use: persistent withdrawal, a social trigger, incorrect medicine use, adverse effects, or inability to obtain treatment. These are different barriers requiring different responses. A previous unsuccessful attempt provides information about treatment fit and access rather than proving that the patient cannot stop.
Apply it
A patient reports that nicotine replacement did not work. Further questioning reveals that medication ran out before a stressful weekend and that the patient also continued vaping. Document the complete exposure and access problem before recommending the same plan unchanged.
Common pitfall: Recording only cigarettes per day can miss other nicotine exposure and confuse an access or technique problem with medication inefficacy.
Assess acute care needs of SUD patients20%
10.Which findings make suspected opioid overdose an emergency?
Unresponsiveness and slow, abnormal, or absent breathing are decisive warning signs of opioid overdose. The immediate response combines emergency activation, an opioid reversal medication when available, and breathing or resuscitation support appropriate to the responder's training. Do not wait for a complete substance history before acting. Co-exposures and uncertain drug contents can complicate the presentation, so suspected overdose requires a clinical emergency response rather than an attempt to prove the exact substance first.
Apply it
A visitor finds a patient difficult to awaken with very slow breathing after suspected opioid use. Activate emergency help, administer available reversal medication, and provide breathing support according to training while remaining with the patient.
Common pitfall: Waiting for certainty about the substance or for a laboratory result delays treatment of the respiratory failure that makes opioid overdose immediately dangerous.
11.Why is observation needed after an opioid reversal response?
Improved alertness after an opioid reversal medication does not guarantee sustained recovery. Opioid effects can outlast the reversal medication, allowing respiratory depression to return. Continue emergency evaluation and observation, reassess breathing and responsiveness, and be prepared to repeat reversal medication according to product instructions and protocol. A transient response is evidence that treatment helped, not proof that the danger has ended. Other substances or medical complications may also remain active.
Apply it
A patient becomes awake after naloxone and wants to leave immediately. Explain recurrence risk, continue monitoring and emergency assessment, and keep additional reversal medication available under protocol rather than treating wakefulness as a discharge criterion.
Common pitfall: One successful reversal does not establish that the opioid has cleared, especially when the exposure is unknown or involves longer-lasting drug effects.
12.How does precipitated opioid withdrawal differ from expected progression?
Buprenorphine combines strong mu-opioid receptor affinity with partial agonism. When it displaces a full agonist in a physically dependent patient, its lower receptor activation can abruptly reduce opioid effect and precipitate withdrawal. The discriminating cue is sudden worsening soon after initiation, interpreted alongside the pre-dose examination and exposure history. Assess vital signs, hydration, severity, and competing causes, then obtain prompt clinician-directed management. This mechanism explains conventional induction safeguards; other initiation protocols require their own clinical plans.
Apply it
After a conventional first buprenorphine dose, a patient develops abruptly worse vomiting, restlessness, and diffuse withdrawal symptoms. Compare the changes with the pre-dose findings and promptly notify the clinician while assessing physiological stability.
Common pitfall: Displacement alone does not explain the mechanism: the abrupt reduction in receptor activation occurs because a partial agonist replaces a full agonist.
SUBOXONE sublingual film — Prescribing Information, updated December 22, 2025
13.When can alcohol withdrawal require more intensive monitoring?
The appropriate withdrawal setting reflects current severity, risk of complicated withdrawal, medical and psychiatric stability, and the ability to monitor safely. Previous withdrawal seizures or delirium, unstable illness, and inadequate support can make a low-intensity plan unsafe even when current symptoms appear limited. Assessment should identify the level of observation and treatment needed now and the capacity to respond if symptoms escalate. Placement cannot be determined by a symptom score alone.
Apply it
A patient with early tremor also has a history of withdrawal delirium and unreliable access to follow-up. Communicate both clinical and environmental risks when arranging withdrawal care instead of selecting the least intensive setting from current symptoms alone.
Common pitfall: Using the present symptom score as the sole placement rule overlooks predictors of deterioration and whether the proposed setting can respond safely.
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
14.How should monitoring change when CIWA-Ar reporting is unreliable?
CIWA-Ar supports alcohol withdrawal assessment but depends substantially on patient reporting and should not be used in delirium. Confusion, communication barriers, pain, and other illnesses can invalidate or distort scores. Within an appropriate monitoring protocol, CAM-ICU assesses delirium through features including acute or fluctuating change and inattention; RASS measures agitation and sedation, helping track arousal and treatment effects. These tools answer different questions and do not independently establish alcohol withdrawal as the cause.
Apply it
A confused patient cannot answer CIWA-Ar questions reliably. Escalate evaluation of the acute change and obtain a protocol using suitable measures, such as CAM-ICU for delirium and RASS for agitation or sedation, together with vital signs and respiratory monitoring.
Common pitfall: Replacing CIWA-Ar with a delirium or sedation score does not create a withdrawal diagnosis or a complete medication algorithm. Interpret each tool according to its purpose.
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
15.Which findings distinguish delirium from uncomplicated alcohol withdrawal?
Delirium involves disturbed attention and awareness with cognitive change, often fluctuating over time. New disorientation or inability to sustain attention should trigger urgent assessment rather than be treated as ordinary anxiety or insomnia. Alcohol withdrawal may cause delirium, but infection, metabolic disturbance, head injury, medications, and other causes must also be considered. The key decision is to escalate monitoring and investigate the acute change while managing suspected withdrawal under the appropriate clinical plan.
Apply it
A patient treated for alcohol withdrawal becomes disoriented and repeatedly loses track of simple questions. Escalate care for acute delirium assessment and physiological monitoring rather than relying only on reassurance or the previous withdrawal score.
Common pitfall: Knowing that a patient drinks heavily does not establish that every episode of confusion is withdrawal delirium or remove the need to investigate alternatives.
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
16.Why is thiamine part of alcohol withdrawal care?
Thiamine supports essential metabolic functions, and deficiency in people with sustained heavy alcohol use can cause serious neurological injury. Withdrawal care should assess nutritional risk and provide thiamine according to the clinical plan, with parenteral administration favored in selected higher-risk circumstances such as poor nutrition or malabsorption. Thiamine does not replace withdrawal medication. ASAM permits glucose and thiamine in either order or concurrently; urgently needed glucose should not be delayed while awaiting thiamine.
Apply it
A poorly nourished patient with heavy alcohol use arrives with hypoglycemia during withdrawal assessment. Provide urgently indicated glucose under protocol and arrange ordered thiamine promptly, rather than postponing correction of hypoglycemia until thiamine is available.
Common pitfall: Treating thiamine as a substitute for withdrawal treatment misses seizure and delirium risk; delaying emergency glucose for a rigid sequence creates another hazard.
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
17.Why can abrupt benzodiazepine cessation be dangerous?
Regular benzodiazepine exposure can produce physical dependence, and abrupt discontinuation or rapid reduction may cause severe withdrawal, including seizures. A prescription history does not eliminate that risk. Establish the medication, pattern, last use, previous withdrawal, and current symptoms, then obtain a safe clinician-directed plan. New severe agitation, confusion, or seizure activity requires urgent assessment. The acute decision is to recognize withdrawal risk rather than recommend sudden cessation simply because long-term use has become concerning.
Apply it
A patient who has taken a benzodiazepine regularly for months stops suddenly and develops escalating tremor and agitation. Assess for severe withdrawal and obtain urgent clinical review instead of advising the patient to endure symptoms unaided.
Common pitfall: An intention to reduce medication harm does not make abrupt cessation safe; physical dependence can occur even when every dose followed a prescription.
FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class
18.Which gabapentinoid combinations increase respiratory concern?
Gabapentin and pregabalin can contribute to serious breathing problems, particularly with opioids or other central nervous system depressants and in patients with respiratory risk factors. Excessive sedation, difficult arousal, and slowed breathing are actionable findings, not merely expected discomfort. Assess the complete medication and substance history, respiratory status, and recent changes. Monitoring should focus on the combined clinical effect because a familiar prescribed drug can become hazardous when another depressant or vulnerability is added.
Apply it
A patient taking prescribed gabapentin becomes difficult to awaken after receiving an opioid and has slow respirations. Initiate urgent respiratory assessment and the appropriate emergency response rather than attributing the change to harmless medication-related sleepiness.
Common pitfall: Assuming that a nonopioid prescription cannot worsen opioid-related respiratory depression overlooks additive depressant effects and patient-specific vulnerabilities such as impaired respiratory function.
19.How should chest pain after stimulant use be assessed?
Chest pain associated with stimulant use requires evaluation for acute coronary syndrome and other serious cardiovascular causes. Stimulant-related agitation or anxiety can coexist with ischemia, so an anxious appearance does not establish a benign explanation. Assess physiological stability and activate the appropriate acute evaluation pathway while communicating the substance history. Treatment of intoxication-related symptoms may proceed alongside medical assessment, but improvement in agitation alone does not prove that a cardiovascular complication has been excluded.
Apply it
A patient reports cocaine use followed by chest pressure and appears frightened. Arrange urgent medical evaluation and monitoring for a cardiovascular complication while assessing intoxication, rather than first testing whether reassurance makes the pain disappear.
Common pitfall: Calling stimulant-associated chest pain a panic symptom before medical evaluation can delay recognition of ischemia, even in a younger patient without known coronary disease.
20.When should suicide risk be reassessed during stimulant recovery?
Suicide risk can change as stimulant intoxication wanes and withdrawal or a post-use decline emerges. Reduced agitation therefore does not necessarily mean reduced psychiatric danger. Reassess suicidal thoughts, intent, available means, psychosis, and the ability to remain safe when mood or behavior changes. A new expression of hopelessness deserves a fresh assessment even if an earlier screen was reassuring. Safety decisions should follow the current presentation rather than a fixed assumption about the expected recovery course.
Apply it
A patient initially denies suicidal thoughts while highly stimulated, then becomes withdrawn and says there is no reason to live. Repeat suicide assessment immediately and implement the indicated safety response rather than relying on the earlier denial.
Common pitfall: A negative screen during intoxication is not a lasting clearance; emerging depression or hopelessness during the post-use period requires renewed assessment and action.
21.How should new symptoms during cannabis cessation be interpreted?
Cannabis withdrawal assessment can include irritability, anxiety, sleep changes, appetite changes, and other discomfort recorded with a structured checklist. Symptom recognition helps monitor distress, but it should not create diagnostic anchoring. Marked confusion, severe psychiatric deterioration, or physiological instability requires a broader assessment rather than automatic attribution to withdrawal. The useful distinction is between tracking a plausible symptom pattern and deciding that all concurrent symptoms share the same explanation without examining their severity or context.
Apply it
A patient reducing cannabis reports insomnia, then develops new confusion. Continue documenting the original symptom pattern, but obtain urgent broader assessment for the acute cognitive change instead of simply increasing the withdrawal checklist score.
Common pitfall: A plausible cessation history can tempt clinicians to explain away new danger signs; symptom checklists should organize observations rather than close the differential assessment.
Marijuana Withdrawal Symptom Checklist · Finding Help for Co-Occurring Substance Use and Mental Disorders
Develop and implement an individualized plan of care15%
22.What establishes readiness for conventional buprenorphine induction?
Conventional induction requires the exposure history and clear objective opioid withdrawal. Findings such as sweating, yawning, rhinorrhea, dilated pupils, piloerection, and gastrointestinal symptoms help distinguish withdrawal from craving or anxiety alone. Interpret the pattern and severity under the selected protocol. Buprenorphine's strong receptor affinity and partial agonism allow it to replace a full agonist while producing less receptor activation, potentially precipitating withdrawal. Other initiation approaches use distinct clinician-directed protocols; conventional readiness criteria should not be generalized to all approaches.
Apply it
For conventional induction, a patient reports craving and anxiety but has normal pupils, dry skin, and no yawning, rhinorrhea, piloerection, or gastrointestinal symptoms. Continue objective reassessment and clarify the initiation plan rather than treating craving as sufficient evidence of readiness.
Common pitfall: An isolated symptom or elapsed interval does not establish readiness. Assess the whole withdrawal pattern and the requirements of the chosen initiation approach.
SUBOXONE sublingual film — Prescribing Information, updated December 22, 2025
23.Which safeguards precede extended-release naltrexone initiation for OUD?
Naltrexone is an opioid antagonist and can precipitate severe withdrawal when physiological dependence remains. The label recommends a minimum opioid-free interval of 7–10 days for patients previously dependent on short-acting opioids. Patients transitioning from methadone or buprenorphine may remain vulnerable for up to two weeks. Review all opioid exposure, current withdrawal, and relevant testing under the initiation plan. Elapsed time, a negative urine test, or a tolerated naloxone challenge cannot guarantee readiness. Accelerated transitions require an appropriate medical setting with close monitoring and capacity to manage precipitated withdrawal.
Apply it
A patient presents ten days after stopping buprenorphine for a scheduled injection. Identify the possible two-week vulnerability, assess recent exposure and withdrawal, and obtain clinician review rather than applying the short-acting-opioid minimum as automatic clearance.
Common pitfall: The recommended intervals are safeguards, not guarantees. Prescribed analgesics and other opioid-containing medicines also matter when checking opioid-free readiness.
24.How should an alcohol withdrawal plan connect treatment, monitoring, and risk?
Benzodiazepines are first-line alcohol withdrawal treatment because they reduce withdrawal symptoms and prevent seizures and delirium. They enhance inhibitory GABA signaling, countering withdrawal-related hyperexcitability. The plan must pair treatment with monitoring of withdrawal response, alertness, respiratory status, and oversedation, especially with other depressants. Symptom-triggered treatment requires valid assessment and suitable staffing; a fixed schedule or another clinician-selected strategy may be needed when reliable symptom assessment is unavailable. Thiamine and supportive care address additional needs but do not replace seizure-preventive treatment.
Apply it
A patient cannot reliably report symptoms because of delirium. Obtain a monitored benzodiazepine treatment strategy using suitable delirium and agitation or sedation measures, with respiratory observation and explicit escalation criteria, rather than mechanically following CIWA-Ar totals.
Common pitfall: A falling agitation level can reflect therapeutic benefit or excessive sedation. Evaluate breathing and arousal as well as apparent withdrawal improvement.
The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
25.How do patient preferences shape an AUD treatment plan?
AUD treatment can include behavioral treatment, medications, mutual support, and care at different levels of intensity. A useful plan matches these options to clinical needs, prior experience, access, and the person's goals. Collaborative planning improves relevance without ignoring withdrawal or other safety concerns. The nursing decision is to translate a broad wish for change into acceptable next actions and follow-up, rather than assume that every person needs the same treatment format or recovery support.
Apply it
A patient wants help with alcohol use but cannot attend a daytime residential program. Explore accessible behavioral care, medication evaluation, and preferred recovery supports, then agree on a concrete first appointment and follow-up rather than abandoning treatment.
Common pitfall: Presenting one program as the only legitimate route can turn an access barrier or preference into an avoidable interruption of otherwise appropriate treatment.
26.Why must benzodiazepine tapering be individualized?
A benzodiazepine taper balances the risks of continued medication exposure against withdrawal and recurrence of the condition being treated. Duration and pattern of use, previous withdrawal, comorbidities, concurrent medicines, and patient response influence the plan. Tapering should be collaborative and monitored, with changes based on tolerance rather than an inflexible schedule. The RN assesses symptoms and functioning and communicates findings so the prescriber can adjust the pace safely when clinically significant problems develop.
Apply it
During a prescribed taper, a patient develops substantial withdrawal symptoms that interfere with daily function. Document the timing and severity and seek prescriber review of the taper pace instead of insisting that the original schedule cannot change.
Common pitfall: A fixed calendar is not evidence that a taper is tolerated; pushing through significant symptoms can undermine safety, trust, and continued participation in care.
Joint Clinical Practice Guideline on Benzodiazepine Tapering
27.How should co-occurring psychiatric and substance-use treatment be coordinated?
Co-occurring mental disorders and SUDs can influence one another and complicate engagement, symptoms, and treatment response. Integrated care addresses both conditions through a coordinated plan rather than requiring one to disappear before the other receives attention. Assessment still distinguishes immediate safety needs from longer-term goals. Nursing implementation includes communicating symptoms, reconciling treatment recommendations, and helping the person access compatible services. Coordination matters because disconnected plans can leave clinically important needs untreated between programs.
Apply it
A patient with persistent depression and OUD is told by separate services to complete the other program first. Help arrange coordinated assessment and treatment of both conditions while ensuring current suicide and overdose risks are addressed.
Common pitfall: Requiring complete substance abstinence before every mental health intervention can leave a co-occurring disorder untreated and make engagement with both services more difficult.
Finding Help for Co-Occurring Substance Use and Mental Disorders
28.Why is contingency management central to stimulant treatment planning?
Contingency management uses planned, tangible reinforcement linked to a clearly defined treatment behavior or outcome. The ASAM/AAAP guideline identifies it as a primary component of stimulant use disorder treatment because of its evidence base. It is structured treatment rather than a vague promise of praise or an improvised punishment system. A plan specifies the target, how it is verified, and how reinforcement follows it, often alongside other psychosocial treatment matched to the patient's needs.
Apply it
A clinic is designing stimulant treatment for patients who struggle to remain engaged. Include an evidence-based contingency management program with explicit targets and verification, and coordinate additional behavioral care rather than relying on unstructured encouragement alone.
Common pitfall: Calling any reward contingency management misses the essential link between a predefined target, objective verification when appropriate, and a consistently delivered reinforcement schedule.
29.How can a cannabis symptom record guide an individualized care plan?
Identify the symptom that most interferes with the patient's goal, then connect symptom monitoring with a functional target and an escalation rule. The Marijuana Withdrawal Symptom Checklist can organize sleep, irritability, anxiety, appetite, craving, and other discomfort. A useful plan specifies who will review these findings and when. The checklist does not select treatment or prove causation; persistent impairment, worsening psychiatric symptoms, or unexpected findings require clinical reassessment.
Apply it
A patient reducing cannabis identifies poor sleep as the main threat to remaining employed. Record baseline sleep symptoms and work impairment, agree on follow-up responsibility, and specify earlier contact if sleep or mental health worsens. Evaluate progress toward reliable work attendance alongside symptom change.
Common pitfall: Collecting scores without a functional goal or a named follow-up responsibility produces data without a usable treatment decision.
Marijuana Withdrawal Symptom Checklist · Finding Help for Co-Occurring Substance Use and Mental Disorders
30.How does combination nicotine replacement address different cravings?
Combination nicotine replacement pairs a patch that provides steady nicotine with a faster-acting product, such as gum or a lozenge, for breakthrough cravings. The products serve complementary purposes rather than duplicate the same delivery pattern. Planning includes selecting suitable products, teaching their correct use, and adding behavioral support. Persistent cravings should prompt review of adherence, technique, and the treatment plan rather than an assumption that nicotine replacement is ineffective for the patient.
Apply it
A patient uses a patch correctly but experiences brief, intense cravings after meals. Discuss adding an appropriate short-acting nicotine product and a coping strategy for that trigger within the cessation plan, with follow-up on use and response.
Common pitfall: Using the patch as though it were an immediate rescue treatment misunderstands its steady delivery; adding products without teaching technique can also limit benefit.
Educate and promote behavioral change15%
31.What should overdose-response teach-back demonstrate?
Effective overdose education checks whether the learner can recognize unresponsiveness and abnormal breathing, summon emergency help, administer the available reversal product, and provide appropriate breathing support. It should also cover staying with the person and the possibility of additional doses or recurrent respiratory depression. Teach-back reveals practical gaps that a statement of understanding may miss. Demonstration should match the actual product available because administration instructions differ among opioid reversal formulations.
Apply it
A family member says they know how to use naloxone but believes emergency help is unnecessary once it works. Ask them to walk through the response and correct that gap while confirming familiarity with their available product.
Common pitfall: Handing over a reversal medication without verifying response steps can leave a family prepared to give one dose but unprepared for persistent or recurrent breathing problems.
32.Why does buprenorphine storage counseling matter?
Buprenorphine can cause serious harm after accidental exposure, especially in children, so storage is part of treatment safety. Teach patients to keep the medicine secured, out of children's sight and reach, and protected from access by others. Counseling should use the product's storage and disposal instructions rather than a generic suggestion to hide medication. A practical storage plan also helps prevent unintended sharing or diversion without undermining the patient's access to prescribed treatment.
Apply it
A parent keeps buprenorphine film in an unlocked kitchen drawer for convenience. Collaboratively choose secure storage that remains usable for the parent, and review product-specific disposal and emergency actions for suspected accidental exposure in the home.
Common pitfall: A high shelf or familiar drawer is not necessarily secure storage; assuming a child-resistant package eliminates the need for careful storage creates false reassurance.
SUBOXONE sublingual film — Prescribing Information, updated December 22, 2025
33.Why can overdose vulnerability increase around naltrexone discontinuation?
Extended-release naltrexone blocks opioid effects, but it does not permanently protect against overdose. After opioid tolerance has fallen, previously tolerated opioid amounts can become dangerous as blockade wanes, after a missed dose, or after discontinuation. Attempts to overcome the blockade with large opioid amounts can also cause fatal overdose. Education should connect these mechanisms to a concrete safety plan, access to reversal medication, and continued treatment contact rather than a general warning to be careful.
Apply it
A patient plans to stop monthly naltrexone and says their previous opioid amount would still be safe. Explain reduced tolerance and changing blockade, arrange overdose-prevention support, and coordinate follow-up around the treatment transition with the team.
Common pitfall: Equating antagonist treatment with lasting immunity from overdose overlooks both attempts to override blockade and the vulnerability created when tolerance is lower after treatment.
34.How does motivational interviewing respond to ambivalence about drinking?
Motivational interviewing explores the person's reasons for and against change while respecting autonomy. Open questions, reflective listening, and permission-based information help the patient connect drinking with personally important goals. The aim is to elicit the person's own motivation and identify a feasible next step, not to win an argument. Ambivalence is useful clinical information: acknowledging it can reveal barriers and values that a directive lecture would leave unexplored.
Apply it
A patient values drinking with friends but worries about missed work. Reflect both concerns, ask how drinking fits with their work goals, and invite them to consider a change they would be willing to try.
Common pitfall: Confrontation may produce defensiveness rather than commitment; agreeing that nothing needs to change also misses the patient's expressed concern and opportunity to explore motivation.
Conduct a Brief Intervention: Build Motivation and a Plan for Change
35.What turns interest in alcohol change into an actionable plan?
A change plan makes the patient's intended behavior, reasons, barriers, supports, and follow-up explicit. The nurse helps select a realistic first step and anticipates situations that could disrupt it. The plan must also account for withdrawal risk before a dependent person abruptly stops drinking. Specific actions are easier to evaluate than a general promise to improve. Follow-up then becomes a chance to learn what worked and revise the plan rather than simply judge compliance.
Apply it
A patient says they want to change their drinking but has no next step. Explore a specific goal and likely barriers, assess whether reduction could create withdrawal risk, and agree on a follow-up contact to review progress.
Common pitfall: A vague commitment can sound encouraging without guiding behavior; urging immediate cessation before checking dependence and withdrawal risk can make an otherwise supportive conversation unsafe.
Conduct a Brief Intervention: Build Motivation and a Plan for Change · The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
36.How should combined sedative risk be explained?
Benzodiazepines, alcohol, opioids, and some other medicines can produce additive central nervous system depression. Education should connect that interaction to observable danger signs such as extreme sedation and slowed breathing. Patients need a shared medication review, disclosure of other substances, and instructions for urgent help when severe symptoms occur. Counseling should also explain that avoiding a hazardous combination does not mean abruptly stopping a regularly used benzodiazepine without a safe tapering plan.
Apply it
A patient takes a benzodiazepine and asks whether alcohol helps with sleep. Explain the combined sedation risk, review other depressants, and arrange safer symptom management while emphasizing that regular benzodiazepine treatment should not be stopped abruptly.
Common pitfall: A simple instruction to stop every sedating medicine immediately can trade interaction risk for withdrawal risk; education must address both hazards in the plan.
FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class · Gabapentin and Pregabalin — Serious Breathing Problems
37.How can contingency management be explained without moral judgment?
Contingency management explains in advance which treatment behavior is being reinforced and how the program recognizes it. The mechanism is behavioral reinforcement, not a judgment about whether a person deserves care. Clear communication about targets, verification, and rewards supports informed participation and predictable implementation. The nurse should distinguish the structured intervention from punishment or withholding ordinary treatment. Reinforcement can be combined with other behavioral approaches to support broader recovery goals.
Apply it
A patient worries that a stimulant treatment program is paying people to be good. Explain the agreed behavioral targets and reinforcement process, invite questions, and clarify how the intervention fits alongside other care and support.
Common pitfall: Describing incentives as rewards for being a good patient adds stigma and hides the specific behavioral mechanism that makes the intervention structured and evaluable.
38.How should hepatitis C results be explained in plain language?
Explain that a reactive antibody result can reflect current infection, a resolved infection, or a false-positive antibody result. The RNA test asks whether virus is currently detectable. Reactive antibody with undetectable RNA generally means no current infection; exposure timing and clinical context determine whether repeat RNA or other follow-up is needed. A person whose infection resolved is not protected from reinfection. End the explanation with the actual next step for that person's result.
Apply it
A patient has reactive HCV antibody and undetectable RNA and believes active infection is confirmed. Explain that RNA did not detect current infection, review recent exposure, and clarify any indicated follow-up without claiming that the antibody proves previous infection.
Common pitfall: Saying only that a test is positive can create a false diagnosis; saying a person can never acquire infection again creates false reassurance.
39.How should nicotine gum technique be taught and checked?
Teach the chew-and-park method: chew nicotine gum slowly until tingling develops, then park it between the cheek and gum. When tingling fades, repeat slow chewing and parking intermittently according to product instructions. Nicotine is absorbed through the lining of the mouth. Continuous vigorous chewing releases nicotine too quickly and promotes swallowing it, which can cause hiccups, nausea, or stomach discomfort and reduce effective oral absorption. Ask the patient to demonstrate the sequence rather than simply confirm understanding.
Apply it
During teach-back, a patient chews nicotine gum continuously like ordinary gum. Stop and demonstrate slow chewing until tingling, parking beside the cheek, and intermittent repetition. Ask the patient to repeat the demonstration and explain where nicotine is absorbed.
Common pitfall: A correct statement about using gum for cravings does not establish correct technique. Observe chewing and parking directly.
Care management, treatment, and evaluation throughout the recovery continuum (including special populations)35%
40.Why are methadone or buprenorphine generally preferred during pregnancy?
For OUD during pregnancy, methadone or buprenorphine is generally preferred to withdrawal management because stable medication treatment supports maternal care and reduces risks associated with recurrence of opioid use. Pregnancy is therefore a reason to coordinate treatment promptly, not to demand abrupt medication cessation. The RN supports informed discussion and communication between addiction and obstetric clinicians. Medication selection and adjustments remain individualized, and expected neonatal monitoring should be discussed without implying that maternal treatment has failed.
Apply it
A pregnant patient on effective OUD medication fears that stopping immediately is the safest choice. Explain the role of ongoing treatment and arrange prompt coordination with the addiction and prenatal teams before any medication change is made.
Common pitfall: Assuming that pregnancy makes abrupt opioid withdrawal the safest option ignores recurrence risk and the benefits of coordinated medication treatment for the pregnant patient.
Treatment of Opioid Use Disorder Before, During, and After Pregnancy
41.How should prenatal and addiction care be linked?
Pregnancy with OUD requires a coordinated plan that connects medication treatment, prenatal care, mental health needs, and practical access barriers. Separate appointments do not automatically create coordinated care; teams need a shared understanding of the treatment plan and follow-up responsibilities. Nursing care identifies missed connections and helps the patient navigate them. The aim is consistent maternal treatment and obstetric follow-up while preparing for delivery, neonatal observation, and postpartum continuity.
Apply it
A pregnant patient attends addiction visits but has missed prenatal appointments because the schedules conflict. Help coordinate appointments and communication between teams, and confirm the next prenatal contact rather than treating addiction attendance as sufficient pregnancy care.
Common pitfall: Counting referrals instead of completed connections can conceal gaps; a patient may appear well linked while no clinician is coordinating the combined pregnancy and OUD needs.
Treatment of Opioid Use Disorder Before, During, and After Pregnancy
42.What does neonatal withdrawal monitoring mean for maternal treatment?
Infants exposed to opioids during pregnancy may need observation for neonatal withdrawal after birth. Anticipating this need supports preparation, communication, and timely infant care; it does not establish that indicated maternal medication treatment was inappropriate. The RN explains that maternal OUD treatment and newborn monitoring address different clinical needs. Planning should connect the family with the delivery and pediatric teams and clarify the expected observation process without promising an outcome that cannot be known before birth.
Apply it
A patient asks whether possible newborn withdrawal means buprenorphine has harmed the treatment plan. Explain why maternal treatment remains important and arrange discussion of newborn monitoring with the obstetric and pediatric teams before delivery to support informed preparation.
Common pitfall: Presenting neonatal withdrawal as proof of maternal treatment failure can encourage unsafe medication changes and stigmatize a complication that should instead prompt planned infant assessment.
Treatment of Opioid Use Disorder Before, During, and After Pregnancy
43.Why does postpartum OUD care need an explicit continuity plan?
OUD treatment needs continue after delivery, when changing demands and interruptions in support can threaten engagement. A postpartum plan should preserve medication access, arrange follow-up, assess mental health and overdose risk, and address practical barriers. Delivery is a transition between services rather than an endpoint for addiction treatment. The RN verifies who will provide ongoing care and whether the patient can obtain it, instead of relying on a general instruction to contact the previous clinic.
Apply it
Before discharge after delivery, a patient has no confirmed OUD follow-up and is uncertain about medication access. Coordinate the next treatment contact and supply arrangements, review overdose prevention, and include mental health follow-up in the discharge plan.
Common pitfall: A routine obstetric discharge appointment does not automatically ensure addiction treatment continuity; unassigned responsibility for medication and follow-up can leave a consequential gap after delivery.
Treatment of Opioid Use Disorder Before, During, and After Pregnancy
44.How long should effective buprenorphine treatment continue?
Buprenorphine maintenance does not have a universally appropriate short endpoint. The prescribing information supports continued treatment while it benefits the patient and contributes to treatment goals. Review effectiveness, adverse effects, patient preference, functioning, and ongoing risk rather than treating a calendar milestone as a requirement to stop. If discontinuation is considered, it requires a planned clinical discussion and safety support. Stable functioning on medication is evidence to evaluate, not proof that the medication has become unnecessary.
Apply it
A patient functioning well on buprenorphine is told that everyone must stop after the same number of months. Review the actual treatment goals and benefits with the clinician and patient instead of applying an arbitrary universal deadline.
Common pitfall: Improvement during medication treatment does not show that stopping it will preserve the same outcome; a fixed duration can overlook continuing benefit and individual risk.
SUBOXONE sublingual film — Prescribing Information, updated December 22, 2025
45.What makes an OUD transition between services safer?
A safer transition preserves access to effective treatment and makes overdose prevention explicit. Confirm the receiving service, the next contact, medication arrangements, and the patient's ability to follow the plan. Review reversal medication and the possibility that reduced tolerance increases risk if opioid use resumes after an interruption. A referral name alone does not demonstrate continuity. The RN evaluates whether the proposed handoff is workable and resolves gaps before the current episode of care ends whenever possible.
Apply it
A patient leaving inpatient care has a clinic number but no appointment or medication plan. Arrange a concrete receiving contact, clarify treatment access, and review overdose-response resources rather than assuming the printed referral completes the handoff safely.
Common pitfall: A completed discharge form can coexist with an unusable plan; continuity depends on actual access, clear responsibility, and the patient's ability to obtain treatment.
Preventing Opioid Overdose · SUBOXONE sublingual film — Prescribing Information, updated December 22, 2025
46.Which outcomes help evaluate ongoing OUD treatment?
OUD treatment evaluation considers withdrawal and craving control, ongoing opioid exposure, adverse effects, safety, adherence, and progress toward functional goals. No single observation captures the entire response. Sedation may signal a safety problem even if craving is reduced, while persistent craving can indicate a need to reassess treatment despite reliable attendance. The RN reports patterns and barriers so the clinician and patient can revise the plan. Evaluation should connect measured changes to meaningful clinical decisions.
Apply it
A patient attends every buprenorphine visit but reports persistent cravings and intermittent opioid use. Document these outcomes and assess adherence and barriers, then coordinate treatment review instead of judging success solely from appointment attendance over time.
Common pitfall: Attendance is useful engagement information, but it does not substitute for evaluating symptoms, safety, substance exposure, and functioning during ongoing medication treatment for OUD.
SUBOXONE sublingual film — Prescribing Information, updated December 22, 2025
47.Why is completed alcohol withdrawal management only a beginning?
Withdrawal management treats the acute physiological consequences of reducing alcohol; it does not by itself treat the longer-term disorder. Once immediate safety is addressed, care should connect the person with ongoing AUD treatment that matches clinical needs and preferences. This may include medication evaluation, behavioral treatment, and recovery supports. The discriminating question at discharge is not only whether withdrawal has resolved, but whether the person has an accessible next step for continuing treatment.
Apply it
A patient finishes monitored alcohol withdrawal and says the disorder is now cured. Explain the difference between acute stabilization and ongoing AUD care, then arrange a specific continuing-treatment contact before discharge from the current treatment setting.
Common pitfall: Equating symptom-free withdrawal completion with recovery can end care at the point when continuing treatment is needed to address recurrent use and longer-term goals.
ASAM — Alcohol Withdrawal Management Guideline · Treatment for Alcohol Problems: Finding and Getting Help
48.How do naltrexone, acamprosate, and disulfiram differ in ongoing AUD care, including after disulfiram is stopped?
Naltrexone blocks opioid receptors, reducing alcohol's rewarding effects and helping reduce heavy drinking. Assess opioid exposure and hepatic safety; opioid analgesia may be blocked. Acamprosate supports maintenance of abstinence in patients already abstinent at initiation. Its exact therapeutic mechanism is not fully understood; effects on glutamate and GABA signaling are proposed. Assess renal function: do not administer acamprosate when creatinine clearance is 30 mL/min or less. Exactly 30 mL/min is contraindicated. Reduced dosing applies to otherwise eligible patients with creatinine clearance above 30 through 50 mL/min. Acamprosate is excreted unchanged through the kidneys, and impaired renal function increases drug exposure. Teach adherence to its three-times-daily schedule. Disulfiram inhibits aldehyde dehydrogenase, causing acetaldehyde accumulation when alcohol is consumed. This aversive mechanism deters drinking rather than directly treating craving. Patients must avoid alcohol and alcohol-containing products throughout treatment and for 14 days after the last dose, because reactions can still occur during that interval. Review hidden alcohol in cough mixtures, sauces, aftershave lotions, and back rubs. Reactions can cause flushing, vomiting, palpitations, and hypotension; severe reactions can cause cardiovascular collapse, arrhythmias, respiratory depression, myocardial infarction, or death. Chest pain, breathing difficulty, fainting, or collapse after alcohol exposure requires immediate emergency assistance. Ensure informed agreement and review hepatic and interaction risks. These medications do not replace acute alcohol-withdrawal treatment.
Apply it
A patient who is abstinent after withdrawal, still needs opioid analgesia, and has normal renal function may be better suited to acamprosate than naltrexone. For an otherwise eligible patient with creatinine clearance of 40 mL/min, acamprosate requires reduced dosing. At exactly 30 mL/min, do not administer it; dose reduction does not override the contraindication. Another patient stopped disulfiram seven days ago and asks whether wine at dinner is now safe. Explain that stopping the tablets does not immediately end alcohol sensitivity: avoid wine and alcohol-containing products for the full 14 days after the last dose. Use teach-back to confirm the patient understands both the interval and hidden alcohol sources. If that patient reports chest pain or breathing difficulty after drinking, activate emergency medical services immediately and communicate the recent disulfiram use.
Common pitfall: Do not describe the disulfiram–alcohol reaction as merely unpleasant or assume that a missed dose or discontinuation makes drinking safe. Even small amounts of alcohol can trigger a reaction, and severity varies. Never recommend a trial drink to test whether sensitivity has resolved. Continue psychosocial support and medication-specific monitoring during treatment transitions.
Treatment for Alcohol Problems: Finding and Getting Help · VIVITROL — Naltrexone Prescribing Information · DailyMed - ACAMPROSATE CALCIUM tablet, delayed release · DailyMed - DISULFIRAM tablet
49.How should recurrence of alcohol use change follow-up?
Recurrence of alcohol use calls for reassessment of safety, treatment needs, barriers, and the fit of the existing plan. It does not establish that treatment is futile or that the person should lose access to care. Ask what preceded the episode, what consequences followed, and what support might reduce future risk. Withdrawal assessment may again be necessary if sustained heavy use has resumed. A revised plan should emerge from the pattern rather than from blame or automatic repetition.
Apply it
After a period of improvement, a patient resumes heavy drinking during a family crisis. Assess current medical and withdrawal risks, explore the circumstances, and coordinate treatment adjustment and support rather than ending care because the previous plan was incomplete.
Common pitfall: Calling recurrence a moral failure discourages disclosure; assuming it requires no change also misses an opportunity to reassess risk and strengthen the treatment plan.
Treatment for Alcohol Problems: Finding and Getting Help · ASAM — Alcohol Withdrawal Management Guideline
50.How should recovery supports be matched to patient needs?
Recovery support is more useful when it matches the person's preferences, access, and practical needs. Mutual-support groups, professional treatment, family involvement when appropriate, and other supports can play different roles. A poor fit with one group does not demonstrate rejection of all recovery help. Ask what the person found helpful or difficult, then identify an acceptable alternative. Support selection should complement clinical treatment and preserve the patient's ownership of the recovery plan.
Apply it
A patient stops attending one alcohol recovery group because its format feels uncomfortable. Explore the specific difficulty and discuss other support formats or treatment options rather than documenting that the patient refuses all help for ongoing recovery.
Common pitfall: Using attendance at one particular group as the sole measure of commitment confuses a program preference with willingness to engage in recovery support.
51.Which AUD outcomes show progress beyond attendance?
AUD follow-up should evaluate drinking-related outcomes, health, functioning, engagement, and progress toward the person's agreed goals. Appointment attendance is one useful process measure, but it cannot establish that the plan is reducing harm or improving daily life. Discuss what has changed, what remains difficult, and whether the current treatment is acceptable and accessible. Repeated review supports adjustments and recognizes improvement without overlooking continuing risk or assuming that one good week establishes sustained recovery.
Apply it
A patient attends counseling regularly but continues missing work after drinking. Review drinking patterns and functional consequences, revisit goals, and coordinate treatment changes instead of marking the plan successful solely because scheduled visits were completed over several weeks.
Common pitfall: Measuring only attendance can hide persistent harm; measuring only a single drinking episode can also obscure broader improvement and the need for a nuanced reassessment.
52.How should follow-up distinguish taper symptoms from the original condition?
During benzodiazepine tapering, anxiety, insomnia, and other symptoms may reflect withdrawal, recurrence of the treated condition, or both. Their relationship to dose reductions, previous symptom patterns, severity, and persistence helps guide reassessment. The RN should document these details and functional effects so the prescriber can adjust the taper and address underlying needs. A new symptom does not automatically justify either abandoning the taper or accelerating it; the clinical pattern determines the next discussion.
Apply it
A patient develops insomnia closely after each taper step but had stable sleep beforehand. Record the timing and impact and obtain prescriber review of withdrawal and underlying sleep needs rather than labeling the patient unmotivated to reduce medication.
Common pitfall: Assuming every symptom proves the original disorder has returned can obscure withdrawal; assuming every symptom is withdrawal can leave an independent condition untreated.
Joint Clinical Practice Guideline on Benzodiazepine Tapering
53.Why should mental health assessment continue after substance use decreases?
Reduced substance use can clarify symptom patterns, but it does not guarantee that a co-occurring mental disorder has resolved. Persistent depression, anxiety, psychosis, or functional impairment warrants continued assessment and treatment coordination. Compare symptoms across time while attending to current safety. This longitudinal approach helps refine understanding without requiring that care wait for perfect diagnostic certainty. The RN monitors both recovery and psychiatric outcomes because improvement in one domain may coexist with substantial difficulty in the other.
Apply it
A patient reports less substance use but continuing severe depression that limits self-care. Coordinate ongoing mental health assessment and reassess safety rather than postponing psychiatric care until the patient has achieved a longer period without substance use.
Common pitfall: Assuming psychiatric recovery automatically follows reduced use can miss persistent illness; a changing substance pattern is a reason to reassess, not to close mental health follow-up.
Finding Help for Co-Occurring Substance Use and Mental Disorders
54.What should follow a detectable hepatitis C RNA result?
Detectable HCV RNA establishes current hepatitis C infection and should lead to counseling, clinical evaluation, and linkage to treatment. The nurse helps the patient understand the result and verifies that referral becomes a completed care connection. Antibody testing alone is not an adequate way to follow a known reactive antibody result. Ongoing exposure history remains relevant to future testing decisions, so infectious-disease care and substance-use care should communicate rather than operate as unrelated episodes.
Apply it
A patient's reactive antibody test is followed by detectable HCV RNA, but no treatment appointment exists. Explain that current infection is established and coordinate a completed clinical connection rather than ordering another antibody test as the next step.
Common pitfall: Repeating antibody testing after current infection is documented delays the useful next action: evaluation and linkage to treatment for the patient with detectable virus.
55.How should persistent functional problems broaden a recovery reassessment?
Recovery evaluation should revisit functioning and co-occurring needs when substance-related symptoms improve but major difficulties remain. The CARN outline includes mental health disorders, medical comorbidities, infectious diseases, and process addictions within co-occurring content. That scope supports broad assessment; it does not establish a diagnosis from one behavior. Explore the nature, timing, consequences, and impaired control associated with the reported problem, then coordinate the relevant clinical assessment instead of attributing all difficulty to the original SUD.
Apply it
A patient reports improved substance control but worsening financial and relationship problems related to gambling. Explore the behavior and consequences and arrange appropriate assessment rather than assuming that reduced substance use means all recovery needs have been met.
Common pitfall: An outline category is not a diagnostic criterion; a concerning behavior warrants careful assessment rather than automatic labeling or dismissal as unrelated to recovery care.
CARN Test Specifications (Blueprint) — Implemented 2026 · Finding Help for Co-Occurring Substance Use and Mental Disorders
56.How should post-acute stimulant symptoms affect follow-up?
Mood, sleep, anxiety, and cognitive symptoms may continue beyond the immediate stimulant intoxication period. Follow-up should assess their severity, trajectory, effect on functioning, and relationship to renewed use, while considering independent psychiatric or medical conditions. Persistence is a reason to assess and support the patient rather than assume deliberate disengagement. The RN communicates clinically important changes and helps coordinate treatment for symptoms that can interfere with participation and recovery.
Apply it
Several weeks into stimulant treatment, a patient reports poor sleep and difficulty concentrating that interfere with appointments. Assess symptom progression and other causes, coordinate clinical review, and address practical barriers rather than interpreting missed visits as simple indifference.
Common pitfall: Expecting all stimulant-related symptoms to disappear immediately can misclassify ongoing impairment as lack of motivation and leave a treatable barrier to engagement unaddressed.
57.What makes contingency management outcomes interpretable?
Contingency management outcomes are interpretable when the target behavior, verification method, reinforcement rules, and implementation are clear. A program cannot be evaluated fairly if targets change unpredictably or planned reinforcement is inconsistently delivered. Nursing follow-up distinguishes problems in participation from problems in how the intervention operates. Track the selected target alongside broader clinical outcomes, because meeting a reinforced behavior is useful evidence but does not summarize every aspect of stimulant recovery or ongoing safety.
Apply it
A clinic reports little benefit from contingency management, but staff frequently delay or omit planned incentives. Review whether the intervention was implemented consistently before concluding that the patient group cannot benefit from this approach to stimulant treatment.
Common pitfall: Attributing poor results entirely to patients ignores implementation failures; counting rewards alone also fails to show whether the intended target and broader outcomes improved.
58.How can stimulant recovery goals extend beyond a substance-use measure?
Stimulant treatment evaluation can include treatment participation, psychiatric and medical stability, sleep, daily functioning, and patient-defined goals alongside substance-use outcomes. These measures identify whether the plan is improving the person's life and where additional care is needed. A single result cannot establish overall recovery or failure. The RN follows trends, explores barriers, and connects findings with actionable changes, such as addressing persistent sleep problems or coordinating mental health treatment while continuing the core stimulant intervention.
Apply it
A patient has improved the program's substance-use target but remains unable to maintain housing appointments because of severe anxiety. Recognize the progress, assess the continuing impairment, and coordinate additional support rather than declaring the treatment plan complete.
Common pitfall: One favorable measure should not erase unresolved functional needs; one continuing difficulty should not erase meaningful improvement in other clinically important areas of stimulant recovery.
59.When should persistent stimulant-associated psychiatric symptoms prompt reassessment?
Psychosis, severe depression, or other major psychiatric symptoms that persist or recur during stimulant treatment need reassessment of current safety, substance exposure, medication factors, and possible co-occurring disorders. The relationship to stimulant use informs evaluation but does not make continued symptoms harmless. Nursing follow-up should identify changes early and coordinate appropriate clinical care. An assumption that symptoms are substance-related must not become a reason to postpone treatment of dangerous or disabling psychiatric symptoms.
Apply it
A patient in stimulant treatment continues hearing threatening voices and is increasingly frightened despite reporting reduced use. Reassess immediate safety and coordinate psychiatric evaluation instead of simply waiting for a longer period without stimulants to pass.
Common pitfall: A suspected substance-related origin does not remove the need to address severe symptoms now; diagnostic uncertainty should guide reassessment rather than justify passive observation.
stud_guideline_document_final.pdf · Finding Help for Co-Occurring Substance Use and Mental Disorders
60.How should discordant cannabis symptom and functioning trends change follow-up?
Compare individual symptom trajectories with baseline, changes in cannabis and other substance exposure, and meaningful activities. A falling total checklist score can coexist with disabling insomnia or anxiety. Persistent impairment despite improvement elsewhere should prompt focused reassessment, including whether symptoms predated cessation or suggest a co-occurring condition. Longitudinal evaluation asks whether care remains necessary and what needs investigation; it does not use a checklist total as an automatic discharge threshold.
Apply it
A patient's overall cannabis symptom score falls, but anxiety predates cannabis cessation and still prevents work attendance. Recognize the improvement while coordinating assessment of the persistent anxiety and confirming who will continue follow-up.
Common pitfall: Improvement in the aggregate does not establish that every symptom is resolving or that a persistent problem has the same cause as the improving symptoms.
Marijuana Withdrawal Symptom Checklist · Finding Help for Co-Occurring Substance Use and Mental Disorders
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the official outline as the full scope: the practice-domain weights and patient-problem weights are separate, intersecting dimensions.
- Prioritize respiratory emergencies, complicated alcohol or sedative withdrawal, stimulant-associated chest pain, delirium, and changing suicide risk.
- Apply AUD symptom thresholds and severity, and distinguish screening from diagnosis, reactive HCV antibody from current infection, and physical dependence from a use disorder.
- Explain buprenorphine affinity and partial agonism, naltrexone initiation safeguards, benzodiazepine treatment of alcohol withdrawal, and the different purposes of AUD maintenance medicines.
- Give the largest share of study time to recovery-continuum decisions: treatment access, pregnancy and postpartum continuity, coordinated comorbidity care, and outcome-based reassessment.
- Practise biopsychosocial formulation, motivational interviewing, concrete change plans, contingency management, and observed nicotine gum teach-back.
A practical preparation plan
1. Map both blueprint dimensions
Build a study grid with the five practice domains as rows and the seven patient-problem categories as columns. Allocate approximately 35% of practice to recovery-continuum decisions and 20% to acute assessment, while giving opioids and alcohol substantial attention across multiple domains.
2. Learn the discriminating pairs
Explain how screening differs from diagnosis, HCV antibody differs from RNA, dependence differs from a use disorder, and spontaneous withdrawal differs from abrupt post-induction deterioration. Apply the AUD 12-month symptom framework and identify the decision each distinction changes.
3. Rehearse acute decisions
For each urgent vignette, name the decisive finding, immediate nursing action, and required reassessment. Include respiratory depression, delirium, previous withdrawal complications, stimulant chest pain, and changing suicidal thoughts. Explain when CIWA-Ar becomes unreliable and the distinct roles of CAM-ICU and RASS.
4. Connect medication mechanisms with safety
Explain why a high-affinity partial opioid agonist can precipitate withdrawal, why an opioid antagonist requires opioid-free initiation safeguards, and why benzodiazepines prevent alcohol withdrawal complications. Compare naltrexone, acamprosate, and disulfiram by purpose and safety checks. Keep conventional buprenorphine induction distinct from other initiation protocols.
5. Practise education and continuity
Write a teach-back exchange, a motivational interviewing response, and a concrete transition plan. Demonstrate nicotine gum technique. Include actual treatment access, receiving-service responsibility, overdose prevention, relevant protective resources, and the patient's preferred goals.
6. Review errors by clinical principle
Complete the 20 questions independently, then explain why every alternative is weaker. Sort errors by domain and patient problem, revisit the relevant concept and source, and use the flashcards for spaced recall of mechanisms and decision cues.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- CARN Exam — Certified Addictions Registered Nurse
- ANCB — Statistics & Studies
- CARN Examination Handbook — Revised January 2026
- CARN Test Specifications (Blueprint) — Implemented 2026
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
- FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class
- Gabapentin and Pregabalin — Serious Breathing Problems
- Preventing Opioid Overdose
- SUBOXONE sublingual film — Prescribing Information, updated December 22, 2025
- VIVITROL — Naltrexone Prescribing Information
- Treatment of Opioid Use Disorder Before, During, and After Pregnancy
- Conduct a Brief Intervention: Build Motivation and a Plan for Change
- Treatment for Alcohol Problems: Finding and Getting Help
- How to Combine Quit Smoking Medicines
- Clinical Screening and Diagnosis for Hepatitis C
- Finding Help for Co-Occurring Substance Use and Mental Disorders
- Marijuana Withdrawal Symptom Checklist
- ASAM — Alcohol Withdrawal Management Guideline
- Joint Clinical Practice Guideline on Benzodiazepine Tapering
- Screen and Assess: Use Quick, Effective Methods
- stud_guideline_document_final.pdf
- alcohol-symptom-checklist.pdf
- DailyMed - ACAMPROSATE CALCIUM tablet, delayed release
- DailyMed - DISULFIRAM tablet
- Alcohol Use Disorder: From Risk to Diagnosis to Recovery | National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Access to Naloxone Can Save a Life During an Opioid Overdose | FDA
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.